For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The hemostasis and tissue sealing agents market in North American is expected to grow at a CAGR of 7.36% over the forecast period 2019-2027. The North American regional market was valued at $ xx million in 2018 and is estimated to extent up to $ xx million by 2027. This regional market at the North America holds the largest share of the hemostats and tissue sealants products due to the aggressive marketing of such devices.
The United States and Canada are considered for this market study. The US has the largest share for the said market in this region. This can be reasoned to the increasing obese & geriatric population that makes up the vast consumer market in the North America. Also, the interest of market players is growing in the underpenetrated sectors that can utilize hemostasis and tissue sealing agents.
There are major competing players for the hemostats and tissue sealants market from the North American region are Hyperbranch Medical Technology, Inc. (Acquired by Stryker), Medtronic PLC, Johnson & Johnson, B.Braun Melsungen AG, Advanced Medical Solutions (AMS) Group PLC, Baxter International Inc., Cohera Medical Inc., C.R. Bard, Inc., Cryolife Inc., CSL Behring, Integra Lifesciences Corp., Pfizer, Inc. and Smith & Nephew PLC.